J. Ragaz

J. Ragaz, A. Coldman, J. Spinelli, 1985, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.

N. Le, J. Spinelli, J. Ragaz, 1997, The New England journal of medicine.

High-Risk Breast Cancer

J. Ragaz, I. Ariel, 1989, Springer Berlin Heidelberg.

Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.

John J Spinelli, Karen Gelmon, J. Spinelli, 2005, Journal of the National Cancer Institute.

The Role of Fine-Needle Aspiration in Determining the Risk of Breast Cancer

J. Ragaz, G. Jong, J. L. Riche, 1989 .

EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer

Luke Hughes-Davies, Carlos Caldas, David S Yu, 2003, Cell.

Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index

Carlos Caldas, Ian O. Ellis, Sarah E. Pinder, 2006, Clinical Cancer Research.

Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes.

J. Ragaz, A. Coldman, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival

W. Woodward, T. Buchholz, J. Ragaz, 2010, Breast Cancer Research and Treatment.

Expression of the Insulin-Like Growth Factor I Receptor and Urokinase Plasminogen Activator in Breast Cancer Is Associated with Poor Survival

T. Nielsen, D. Huntsman, C. Gilks, 2004, Cancer Research.

A decision analysis of the effect of avoiding axillary lymph node dissection in low risk women with invasive breast carcinoma

J. Ragaz, C. Grau, I. Olivotto, 2000, Cancer.

Preoperative (Neoadjuvant) Chemotherapy

J. Goldie, P. Band, J. Ragaz, 1986, Recent Results in Cancer Research.

Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer.

K. Gelmon, D. Ayers, A. Tolcher, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOR BREAST CANCER Updates from the 2005 San Antonio Breast Cancer Symposium

J. Ragaz, 2006 .

High-Risk Breast Cancer: Definition of the Risk

J. Ragaz, I. Ariel, 1989 .

Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.

J. Ragaz, N. Macpherson, A. Brodie, 2004, Journal of the National Cancer Institute.

Tamoxifen and conjugated estrogens (Premarin) followed by sequenced methotrexate and 5-FU in refractory advanced breast cancer.

E. Eisenhauer, J. Ragaz, K. Pritchard, 1984, Cancer treatment reports.

The 21-gene assay and its impact on breast cancer treatment

J. Ragaz, 2010 .

comment The 21-gene assay and its impact on breast cancer treatment

Frcpc, J. Ragaz, 2010 .

THE 21-GENE ASSAY: Impact on breast cancer in Canada

J. Ragaz, 2009 .

BIOLOGICAL THERAPIES FOR BREAST CANCER

J. Ragaz, 2006 .

Adjuvant systemic therapy and survival after breast cancer.

K. Gelmon, J. Ragaz, I. Olivotto, 1994, The New England journal of medicine.

A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer.

K. Gelmon, D. Ayers, A. Tolcher, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant (preoperative) chemotherapy for breast cancer

J. Goldie, A. Coldman, J. Spinelli, 1985, Cancer.

Status of aromatase inhibitors in relation to other breast cancer treatment modalities.

J. Ragaz, 1999, Endocrine-related cancer.

Hormone Replacement Therapy: A Critical Review

J. Ragaz, J. Budlovský, 2010, Management of Breast Diseases.

The SUVmax for 18F-FDG Correlates With Molecular Subtype and Survival of Previously Untreated Metastatic Breast Cancer

J. Ragaz, YingJian Zhang, Jian Zhang, 2013, Clinical nuclear medicine.

Adverse association of expressed vascular endothelial growth factor (VEGF) with long-term outcome of stage I-III breast cancer (BrCa), with co-expression data of VEGF and Her2, Cox2, uPA and ER. Results from the British Columbia Tissue Microarray Project.

T. Nielsen, D. Huntsman, J. Ragaz, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

THE BENEFITS OF SEQUENCING ADJUVANT TAMOXIFEN AND ANASTROZOLE IN POSTMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST CANCER: 5 YEAR-ANALYSIS OF ABCSG TRIAL 8. SABCS 2005 ABSTRACT 13.

J. Ragaz, I. Bence-Bruckler, I. Bence‐Bruckler, 2006 .

Treatment of estrogen deficiency symptoms in women surviving breast cancer. The Hormone Foundation, Canadian Breast Cancer Research Initiative, National Cancer Institute of Canada, Endocrine Society, and the University of Virginia Cancer Center and Woman's Place.

T. Powles, H. Parnes, H. Burger, 1999, The Journal of clinical endocrinology and metabolism.

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer

J. Ragaz, Bing-he Xu, Zefei Jiang, 2014, International journal of cancer.

Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group.

N. Boyd, J. Ragaz, M. Knowling, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiation impact in breast cancer

J. Ragaz, 2009, Breast Cancer Research.

Significance of axillary lymph node extranodal soft tissue extension and indications for postmastectomy irradiation

J. Ragaz, S. Jackson, 2000, Cancer.

Randomized adjuvant trials in oncology: a necessity or time-consuming luxury?

J. Ragaz, 2010, Breast Cancer Research.

Adjuvant targeted therapy in early breast cancer

K. Gelmon, J. Mackey, J. Ragaz, 2009, Cancer.

Experimental basis and clinical reality of preoperative (neoadjuvant) chemotherapy in breast cancer.

J. Goldie, J. Ragaz, V. Basco, 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Breast cancer mortality reduction in the western world: therapeutic versus diagnostic interventions. Implications for cancer care organization processes.

J. Spinelli, J. Ragaz, E. Franco, 2009 .

Early results of the British Columbia breast cancer preoperative (Neo-Adjuvant) chemotherapy trial

J. Goldie, J. Ragaz, V. Basco, 1991 .

Emerging modalities for adjuvant therapy of breast cancer: neoadjuvant chemotherapy.

J. Ragaz, 1986, NCI monographs : a publication of the National Cancer Institute.

Aminoglutethimide-induced hematologic toxicity: worldwide experience.

A. Buzdar, J. Ragaz, R. Santen, 1985, Cancer treatment reports.

Thrombocytopenia after combination therapy with aminoglutethimide and tamoxifen: which drug is to blame?

J. Ragaz, N. Buskard, M. Manji, 1984, Cancer treatment reports.

Predictive biomarkers for anthracycline benefit in early breast cancer : When do we act ?

J. Ragaz, 2009 .

Comparative Analysis of Breast Cancer (BrCa) Mortality Reduction among Regions of Canada between 1950 – 2004: Impact of Systemic and Diagnostic Guidelines after 1977, with Model Definition of Number of Potentially Avoided Annual Deaths (N-PAAD).

J. Ragaz, H. Wong, H. Qian, 2009 .

PP16 Metronomic weekly use of zoledronic acid for breast cancer with bone metastases has more potent antitumor and bone-preserving effects than conventional zoledronic acid given every-four-weeks

J. Ragaz, Z. Shao, X. Xu, 2009 .

Breast cancer survival advantage with radiotherapy

J. Ragaz, J. Spinelli, A. Coldman, 2000, The Lancet.

The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer

J. Ragaz, YingJian Zhang, Jian Zhang, 2013, BMC Cancer.

Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial

J. Ragaz, Jiong Wu, Z. Shao, 2020, Investigational New Drugs.

ANNUAL MEETING OF ThE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASC0)

J. Ragaz, B. Bultz, 2010 .

Ventricular arrhythmia and adrenal insufficiency after fluorouracil: new side effects of an old drug.

J. Ragaz, L. N. Harris, 1993, Journal of the National Cancer Institute.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

S. Steinberg, E. Rutgers, E. Winer, 2018, The Lancet. Oncology.

Breast Cancer Research and Treatment 2001 Reviewers

D. Berry, L. Holmberg, D. Alberts, 2004, Breast Cancer Research and Treatment.

Significance of axillary lymph node extranodal soft tissue extension and indications for postmastectomy irradiation

J. Ragaz, S. Jackson, 2000, Cancer.

A Critique of the Breast Cancer Clinical Research Process SAVE TIME, MONEY AND LIVES BY REDUCING REPETITIVE TESTING OF NEW AGENTS AGAINST PLACEBO

J. Ragaz, 2007 .